PETROS PHARMACEUTICALS INC (PTPI)
US71678J2096 - Common Stock
Overall PTPI gets a fundamental rating of 2 out of 10. We evaluated PTPI against 194 industry peers in the Pharmaceuticals industry. PTPI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PTPI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PTPI has reported negative net income.
PTPI had a negative operating cash flow in the past year.
In the past 5 years PTPI always reported negative net income.
PTPI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PTPI has a worse Return On Assets (-115.72%) than 81.25% of its industry peers.
The Return On Equity of PTPI (-317.07%) is worse than 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.72% | ||
| ROE | -317.07% | ||
| ROIC | N/A |
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTPI has a Gross Margin of 73.80%. This is amongst the best in the industry. PTPI outperforms 80.73% of its industry peers.
In the last couple of years the Gross Margin of PTPI has declined.
The Profit Margin and Operating Margin are not available for PTPI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%
2. Health
2.1 Basic Checks
PTPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTPI has been increased compared to 1 year ago.
Compared to 5 years ago, PTPI has more shares outstanding
The debt/assets ratio for PTPI has been reduced compared to a year ago.
2.2 Solvency
PTPI has an Altman-Z score of -8.19. This is a bad value and indicates that PTPI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PTPI (-8.19) is worse than 72.40% of its industry peers.
PTPI has a Debt/Equity ratio of 0.62. This is a neutral value indicating PTPI is somewhat dependend on debt financing.
PTPI has a worse Debt to Equity ratio (0.62) than 67.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.19 |
ROIC/WACCN/A
WACC7.38%
2.3 Liquidity
A Current Ratio of 1.40 indicates that PTPI should not have too much problems paying its short term obligations.
PTPI's Current ratio of 1.40 is on the low side compared to the rest of the industry. PTPI is outperformed by 77.60% of its industry peers.
A Quick Ratio of 1.26 indicates that PTPI should not have too much problems paying its short term obligations.
The Quick ratio of PTPI (1.26) is worse than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.26 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.17% over the past year.
PTPI shows a strong growth in Revenue. In the last year, the Revenue has grown by 167.72%.
PTPI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -16.15% yearly.
EPS 1Y (TTM)0.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.15%
Revenue 1Y (TTM)167.72%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Sales Q2Q%-28.57%
3.2 Future
The Earnings Per Share is expected to grow by 15.62% on average over the next years. This is quite good.
Based on estimates for the next years, PTPI will show a very strong growth in Revenue. The Revenue will grow by 29.25% on average per year.
EPS Next Y58.64%
EPS Next 2Y33.73%
EPS Next 3Y21.34%
EPS Next 5Y15.62%
Revenue Next Year-29.45%
Revenue Next 2Y-15.69%
Revenue Next 3Y-10.88%
Revenue Next 5Y29.25%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PTPI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTPI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PTPI's earnings are expected to grow with 21.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.73%
EPS Next 3Y21.34%
5. Dividend
5.1 Amount
PTPI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PETROS PHARMACEUTICALS INC
NASDAQ:PTPI (11/22/2024, 10:51:27 AM)
0.27
+0.01 (+5.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.70M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.72% | ||
| ROE | -317.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.8% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)0.17%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y58.64%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)167.72%
Revenue growth 3Y-15.24%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y